AI and the Future of Drug Discovery: Why Omics Data Comes First
Investor's Business Daily recently explored how artificial intelligence is reshaping biotech and drug development and DNAnexus’ very own CEO Thomas Laur was among the industry voices weighing in on what it will actually take to get there.
Thomas's perspective is clear: we're still in the early innings of applying AI to biology, and the potential to transform drug discovery and therapy development is enormous. But that potential won't be realized unless we address the omics data AI advancements will depend on. As an industry, we need to do the rigorous, sometimes unglamorous work of organizing and harmonizing scientific data and infrastructure before AI models can be trusted with decisions that affect patient health. The stakes are too high to cut corners.
At DNAnexus, this belief shapes everything we build. We're convinced that AI-ready omics data — not just more powerful models — is the key to unlocking the complexity of human biology and understanding how disease progresses. It's why we remain intensely focused on the convergence of Omics+AI, building the infrastructure that allows AI to actually deliver on its promise in life sciences.
We invite you to read the full article below and hear more from Thomas and other thought leaders shaping this next chapter of drug discovery.